Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome

Franziska Meyr; Gabriele Escherich; Georg Mann; Thomas Klingebiel; Andreas Kulozik; Claudia Rossig; Martin Schrappe; Günter Henze; Arend von Stackelberg; Johann Hitzler

doi:10.1111/bjh.12348

Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome

Standard

Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. / Meyr, Franziska; Escherich, Gabriele; Mann, Georg; Klingebiel, Thomas; Kulozik, Andreas; Rossig, Claudia; Schrappe, Martin; Henze, Günter; von Stackelberg, Arend; Hitzler, Johann.

in: BRIT J HAEMATOL, Jahrgang 162, Nr. 1, 01.07.2013, S. 98-106.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Meyr, F, Escherich, G, Mann, G, Klingebiel, T, Kulozik, A, Rossig, C, Schrappe, M, Henze, G, von Stackelberg, A & Hitzler, J 2013, 'Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome', BRIT J HAEMATOL, Jg. 162, Nr. 1, S. 98-106. https://doi.org/10.1111/bjh.12348

APA

Meyr, F., Escherich, G., Mann, G., Klingebiel, T., Kulozik, A., Rossig, C., Schrappe, M., Henze, G., von Stackelberg, A., & Hitzler, J. (2013). Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. BRIT J HAEMATOL, 162(1), 98-106. https://doi.org/10.1111/bjh.12348

Vancouver

Meyr F, Escherich G, Mann G, Klingebiel T, Kulozik A, Rossig C et al. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome. BRIT J HAEMATOL. 2013 Jul 1;162(1):98-106. https://doi.org/10.1111/bjh.12348

Bibtex

@article{43a88884ba3749019a98136ae6d63cc7,

title = "Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome",

abstract = "Children with Down syndrome (DS) have a greater risk for developing both acute lymphoblastic leukaemia (ALL) and significant adverse effects of chemotherapy. We investigated their outcome with, and tolerance of, treatment protocols for relapsed ALL optimized in the paediatric population without DS. Probability of survival and causes of treatment failure were determined for 49 children with DS and a matched cohort of 98 children without DS among 2160 children treated for relapsed ALL in clinical trials conducted by the Berlin-Frankfurt-M{\"u}nster ALL Relapse Study Group between 1983 and 2012. Despite more favourable ALL relapse characteristics, children with DS experienced lower event-free (EFS) and overall survival (OS) than the control group without DS (EFS 17 ± 08% vs. non-DS 41 ± 06%, P = 0·006; OS 17 ± 09% vs. non-DS 51 ± 06%, P < 0·001). Children with DS developed more frequently fatal complications of treatment (34 ± 07% vs. non-DS 10 ± 04%, P < 0·001). During the last decade, EFS and OS were no longer significantly different in children with and without DS (EFS 31 ± 09% vs. 36 ± 09%, P = 0·399; OS 31 ± 12% vs. 53 ± 09%, P = 0·151). DS proved an independent prognostic factor of outcome after ALL relapse. Induction deaths and treatment-related mortality but not subsequent relapse were the main barrier to successful outcomes of relapse therapy in children with DS.",

keywords = "Adolescent, Cause of Death, Child, Child, Preschool, Down Syndrome, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Recurrence, Treatment Outcome",

author = "Franziska Meyr and Gabriele Escherich and Georg Mann and Thomas Klingebiel and Andreas Kulozik and Claudia Rossig and Martin Schrappe and G{\"u}nter Henze and {von Stackelberg}, Arend and Johann Hitzler",

note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",

year = "2013",

month = jul,

day = "1",

doi = "10.1111/bjh.12348",

language = "English",

volume = "162",

pages = "98--106",

journal = "BRIT J HAEMATOL",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "1",

}

RIS

TY - JOUR

T1 - Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome

AU - Meyr, Franziska

AU - Escherich, Gabriele

AU - Mann, Georg

AU - Klingebiel, Thomas

AU - Kulozik, Andreas

AU - Rossig, Claudia

AU - Schrappe, Martin

AU - Henze, Günter

AU - von Stackelberg, Arend

AU - Hitzler, Johann

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Children with Down syndrome (DS) have a greater risk for developing both acute lymphoblastic leukaemia (ALL) and significant adverse effects of chemotherapy. We investigated their outcome with, and tolerance of, treatment protocols for relapsed ALL optimized in the paediatric population without DS. Probability of survival and causes of treatment failure were determined for 49 children with DS and a matched cohort of 98 children without DS among 2160 children treated for relapsed ALL in clinical trials conducted by the Berlin-Frankfurt-Münster ALL Relapse Study Group between 1983 and 2012. Despite more favourable ALL relapse characteristics, children with DS experienced lower event-free (EFS) and overall survival (OS) than the control group without DS (EFS 17 ± 08% vs. non-DS 41 ± 06%, P = 0·006; OS 17 ± 09% vs. non-DS 51 ± 06%, P < 0·001). Children with DS developed more frequently fatal complications of treatment (34 ± 07% vs. non-DS 10 ± 04%, P < 0·001). During the last decade, EFS and OS were no longer significantly different in children with and without DS (EFS 31 ± 09% vs. 36 ± 09%, P = 0·399; OS 31 ± 12% vs. 53 ± 09%, P = 0·151). DS proved an independent prognostic factor of outcome after ALL relapse. Induction deaths and treatment-related mortality but not subsequent relapse were the main barrier to successful outcomes of relapse therapy in children with DS.

AB - Children with Down syndrome (DS) have a greater risk for developing both acute lymphoblastic leukaemia (ALL) and significant adverse effects of chemotherapy. We investigated their outcome with, and tolerance of, treatment protocols for relapsed ALL optimized in the paediatric population without DS. Probability of survival and causes of treatment failure were determined for 49 children with DS and a matched cohort of 98 children without DS among 2160 children treated for relapsed ALL in clinical trials conducted by the Berlin-Frankfurt-Münster ALL Relapse Study Group between 1983 and 2012. Despite more favourable ALL relapse characteristics, children with DS experienced lower event-free (EFS) and overall survival (OS) than the control group without DS (EFS 17 ± 08% vs. non-DS 41 ± 06%, P = 0·006; OS 17 ± 09% vs. non-DS 51 ± 06%, P < 0·001). Children with DS developed more frequently fatal complications of treatment (34 ± 07% vs. non-DS 10 ± 04%, P < 0·001). During the last decade, EFS and OS were no longer significantly different in children with and without DS (EFS 31 ± 09% vs. 36 ± 09%, P = 0·399; OS 31 ± 12% vs. 53 ± 09%, P = 0·151). DS proved an independent prognostic factor of outcome after ALL relapse. Induction deaths and treatment-related mortality but not subsequent relapse were the main barrier to successful outcomes of relapse therapy in children with DS.

KW - Adolescent

KW - Cause of Death

KW - Child

KW - Child, Preschool

KW - Down Syndrome

KW - Female

KW - Follow-Up Studies

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Prognosis

KW - Recurrence

KW - Treatment Outcome

U2 - 10.1111/bjh.12348

DO - 10.1111/bjh.12348

M3 - SCORING: Journal article

C2 - 23594030

VL - 162

SP - 98

EP - 106

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 1

ER -